BioAtla Inc (BCAB)
2.54
+0.29
(+12.89%)
USD |
NASDAQ |
Apr 26, 16:00
2.54
0.00 (0.00%)
After-Hours: 20:00
BioAtla PS Ratio
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| December 30, 2020 | 316.54 |
| December 29, 2020 | 307.44 |
| December 28, 2020 | 311.81 |
| December 24, 2020 | 289.52 |
| December 23, 2020 | 293.89 |
| Date | Value |
|---|---|
| December 22, 2020 | 303.90 |
| December 21, 2020 | 292.80 |
| December 18, 2020 | 318.45 |
| December 17, 2020 | 319.91 |
| December 16, 2020 | 282.24 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
282.24
Minimum
Dec 16 2020
319.91
Maximum
Dec 17 2020
303.65
Average
305.67
Median
PS Ratio Benchmarks
| Marinus Pharmaceuticals Inc | 2.436 |
| Equillium Inc | 1.646 |
| Poseida Therapeutics Inc | 2.969 |
| Biomea Fusion Inc | -- |
| Candel Therapeutics Inc | 1491.10 |
PS Ratio Related Metrics
| Price to Book Value | 1.729 |
| Price | 2.54 |
| Earnings Yield | -102.0% |
| Market Cap | 122.17M |